Anti-Hypertensive Drugs Market: Global Market Size, Industry Share, Approaches and Forecast 2018-202

The latest market report published by Credence Research, Inc. “Global Anti-Hypertensive Drugs Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023,” the global anti-hypertensive drugs  market was valued at USD 32,214.3 Mn in 2015, and is expected to reach USD 34,925.7 Mn by 2023, expanding at a CAGR of 1.2% from 2016 to 2023.


Browse the full report Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023 report at http://www.credenceresearch.com/report/anti-hypertensive-drugs-market


Market Insights


Hypertension is commonly observed chronic condition, in which the blood pressure is elevated abnormally both systolic and diastolic. This is major risk factor for causing cardiovascular, renal or endocrine disorder. The normal blood pressure level is 120-140mm Hg systolic and 60-90mm Hg diastolic any elevation above it is considered as hypertension. The major reason for the rise in prevalence of hypertension is lifestyle change, unhealthy food habits and demographic ageing. Anti-hypertensive drugs are used to reduce the level of blood pressure, different drug class of drugs with different mechanism of action exist in the market. The antihypertensive market is growing with increased patient pool especially geriatric population and extensive research and development for novel pipeline drug. The global antihypertensive market show robust growth in forecast period, but it face threat of genericization and increased competition due to patent expiry.


Anti-Hypertensive are categorized by drug class type as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. ACE inhibitor occupies the largest market share in terms of value due to mechanism of action and is preferred in geriatric population and diabetes patient as first line of treatment as antihypertensive drug. Beta blockers follow next in line due to preference of physician over diuretic, which are most commonly used.


Based on the drug class type, the global Anti-hypertensive drugs market is segmented as follows:


  • Diuretics

  • ACE inhibitors

  • ARBs

  • Calcium Channel Blockers

  • Beta - Adrenergic blocker

  • Alpha - Adrenergic blocker

  • Central Sympatholyics

  • Renin inhibitors

  • Vasodilators

As of the current market scenario, North America is the largest regional market for anti-hypertensive drugs market, followed by the Europe and Asia Pacific. The major factors driving the North America rise in prevalence of hypertension and other associated chronic disease especially in geriatric population, novel drugs in pipeline and upcoming use of combination therapies. Europe major market contributor are UK, Germany, France, Italy and Spain due to factors such as increase in prevalence of hypertension and unmet need for treatment of chronic disease, health care program planning and expenditure. Asia-Pacific is the fastest growing market due to rise population and incidence of chronic diseases due to alteration in lifestyle changes; and health care infrastructure and government expenditure. Thus developed market dominates the antihypertensive drugs market, with developing economies booming at fast rate.


Market Competition Assessment:


Key players in the global Anti-Hypertensive drugs market are


Novartis AG, Astra Zeneca, Pfizer Inc., Acetelion Ltd, Sanofi S.A., Merck & Co., Boehringer Ingelheim, Lupin Limited, Johnson & Johnson Ltd.,  Astra Zeneca Plc, Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceutical, Bayer AG etc.


Key Market Movements:


  • Rising prevalence of hypertension due to various factors such as growing population, change in unhealthy lifestyle etc.

  • Extensive R&D for new treatment regimen and new drug approval in pipeline

  • Evolving use of combination therapy to lower the blood pressure and decrease in adverse effect

Browse the full report Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023 report at http://www.credenceresearch.com/report/anti-hypertensive-drugs-market


 


 Blog: http://www.mobilecomputingtoday.co.uk/5913/pharmacogenomics-market-expected-reach-usd-11-94-2024-credence-research/


Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease. There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used drugs are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers.


Which type of medication to use initially for hypertension has been the subject of several large studies and resulting national guidelines. The fundamental goal of treatment should be the prevention of the important endpoints of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered.  The several classes of antihypertensive differ in side effect profiles, ability to prevent endpoints, and cost. The choice of more expensive agents, where cheaper ones would be equally effective, may have negative impacts on national healthcare budgets. As of 2009, the best available evidence favors the thiazide diuretics as the first-line treatment of choice for high blood pressure when drugs are necessary. Although clinical evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (from both efficacy and cost points of view), an ACE inhibitor is recommended by NICE in the UK for those under 55 years old. Source: Wikipedia


 Latest Reports: https://globenewswire.com/news-release/2018/03/13/1421270/0/en/Global-Algae-Products-Market-is-Expected-to-Reach-US-44-7-Billion-By-2023-Credence-Research.html


About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.


Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com